1. 3-nitroimidazo[1,2-b]pyridazine as a novel scaffold for antiparasitics with sub-nanomolar anti-Giardia lamblia activity
- Author
-
Yang Zheng, Joachim Müller, Stefan Kunz, Marco Siderius, Louis Maes, Guy Caljon, Norbert Müller, Andrew Hemphill, Geert Jan Sterk, and Rob Leurs
- Subjects
3-nitroimidazo[1,2-b]pyridazine ,Synthesis ,Giardia lamblia ,3′,5′-cyclic nucleotide phosphodiesterase ,In vitro ,Infectious and parasitic diseases ,RC109-216 - Abstract
As there is a continuous need for novel anti-infectives, the present study aimed to fuse two modes of action into a novel 3-nitroimidazo[1,2-b]pyridazine scaffold to improve antiparasitic efficacy. For this purpose, we combined known structural elements of phosphodiesterase inhibitors, a target recently proposed for Trypanosoma brucei and Giardia lamblia, with a nitroimidazole scaffold to generate nitrosative stress. The compounds were evaluated in vitro against a panel of protozoal parasites, namely Giardia lamblia, Trypanosoma brucei, T. cruzi, Leishmania infantum and Plasmodium falciparum and for cytotoxicity on MRC-5 cells. Interestingly, selective sub-nanomolar activity was obtained against G. lamblia, and by testing several analogues with and without the nitro group, it was shown that the presence of a nitro group, but not PDE inhibition, is responsible for the low IC50 values of these novel compounds. Adding the favourable drug-like properties (low molecular weight, cLogP (1.2–4.1) and low polar surface area), the key compounds from the 3-nitroimidazo[1,2-b]pyridazine series can be considered as valuable hits for further anti-giardiasis drug exploration and development.
- Published
- 2022
- Full Text
- View/download PDF